On September 8, Charles River Laboratories (NYSE:CRL) said its newly automated cartridge manufacturing suite for Endosafe endotoxin testing had reached full operational capacity in the third quarter, a milestone it had been building toward since the system went fully live in July. The timing matters. Charles River has spent much of 2026 shedding businesses and narrowing its focus, and this factory upgrade is the clearest sign yet of what that leaner company is supposed to look like.
The Automation Payoff Shows Up
The results from the automated suite are specific enough to matter. Since going fully operational, Charles River has cut scrap rates by 2% compared with manual cartridge production, reduced invalid cartridge rates by 13%, and lifted capacity across its Trillium and LAL cartridge lines by 14%. Labor productivity is up 87%, which the company says frees skilled workers for higher-value projects instead of routine inspection. That inspection is now total rather than spot-checked. Every cartridge gets scanned for thickness, reagent fill, and seal integrity, and carries a unique ID for traceability, a level of scrutiny manual sampling never offered.
That operational lift shows up in the numbers. The Manufacturing segment’s non-GAAP operating margin climbed to 37.8% in the second quarter from 32.8% a year earlier, and organic revenue in the segment grew 1.3%, powered by the Microbial Solutions business that runs the Endosafe line. Meanwhile, the Discovery and Safety Assessment segment posted its highest net book-to-bill ratio in nearly four years, which pushed Charles River to raise both its revenue and non-GAAP earnings per share guidance for 2026. The company has also been picking up higher-profile relationships, joining Eli Lilly’s TuneLab platform for non-clinical testing and working with Arovella Therapeutics on next-generation sequencing services gained through the PathoQuest acquisition.
The Numbers Still Sting
The headline figures are messier. Charles River posted a GAAP loss per share of $0.03 in the second quarter, reversing the $1.06 per share it earned a year earlier, largely because of a $63.7 million loss tied to the CDMO and Cell Solutions divestitures. Total revenue fell 2.7% year over year to $1.00 billion, and while organic revenue growth of 0.1% was the strongest reading since the third quarter of 2023, that bar was low to begin with.
Profitability is under pressure even where the top line held up. Non-GAAP operating margin slipped to 20.5% from 22.1% a year earlier, and non-GAAP earnings per share fell 3.2% to $3.02, weighed down by higher study-related direct costs in Discovery and Safety Assessment and rising unallocated corporate costs. That segment’s non-GAAP margin actually fell to 25.6% from 27.4% even as study volume improved, which suggests more work is not yet translating into more profit. Research Models and Services is still shrinking too, with revenue down 1.8% and its non-GAAP margin down to 24.5% from 25.3%, as demand for small research models in North America keeps softening.
What The Market Is Pricing
Hedge fund ownership of Charles River rose from 43 funds to 47 in the most recent quarter, which points to institutions adding rather than trimming. Short interest sits at 6.14% of float, enough to reflect a real bear camp without signaling outright crowding. The stock trades at a forward price-to-earnings ratio of 22.47 as of September 21, a multiple that assumes the margin pressure in DSA and RMS eases from here. That combination, rising fund ownership against a moderate short base and a full-looking multiple, suggests the market has not fully settled which side of this story wins out.
Two Stories, One Stock
Charles River is running two stories at once. One is a manufacturing business getting measurably better at making a product it has sold for years, with every automation metric pointing the same direction. The other is a company still absorbing the cost of cutting itself down to size, with margins in its largest segments moving the wrong way even as revenue stabilizes. For the automation gains to matter to the bottom line, they need to spread beyond one product line inside one segment. For the margin pressure to fade, DSA’s stronger bookings need to convert into profit rather than just revenue.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
